Christopher Winrow is CSO at Lucy Therapeutics, Inc., where he leads a team targeting mitochondrial dysfunction in CNS diseases. Dr. Winrow has more than 20 years of neuroscience drug discovery and development experience in both large pharma and biotech companies including Merck & Co., Inc., Ironwood Pharmaceuticals and Cyclerion Therapeutics. He has worked in CNS areas including Parkinson’s disease, Alzheimer’s disease, dementia, sleep disorders, autism and mitochondrial diseases. Dr. Winrow led teams from screening through clinical POC and approvals. He led the Belsomra® discovery team from screening to regulatory approval in less than 10 years, resulting in launches in the U.S., Japan, Australia and Canada. Dr. Winrow has authored more than 75 publications and 15 eIND/INDs and is co-inventor on multiple patents. He serves on the scientific advisory board for the Phelan-McDermid Syndrome Foundation. Dr. Winrow completed his PhD at the University of Alberta and postdoctoral fellowship at the Salk Institute.